LGND
Ligand Pharmaceuticals Incorporated
306.80$
+1.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +40.5% | -65.8% | +131.1% | +17.6% | +58.7% | +26.6% | +46.0% | +15.9% | +8.0% | -20.2% | -90.9% | +111.8% | +42.6% | -39.6% | +27.6% | +4.5% | +56.0% | +31.8% | +11.4% | +51.5% | +29.5% | +78.2% | -52.2% | +36.0% | +47.7% | -18.8% | -33.1% | +27.3% | +60.4% | |
| – | – | – | – | -47.8% | +762.0% | +45.6% | +55.7% | +25.9% | +0.1% | -43.2% | +159.4% | -29.0% | -63.5% | -57.6% | -24.0% | -26.6% | +59.2% | +59.4% | -36.4% | -4.1% | -3.7% | +18.1% | +79.1% | +168.1% | +104.4% | -15.0% | -33.7% | -68.4% | -40.5% | |
| – | +33.1% | -58.7% | +48.8% | +23.0% | +34.2% | +22.3% | +43.5% | +13.0% | +10.6% | -13.5% | -89.1% | +111.8% | -13.2% | -0.7% | +6.8% | +10.6% | +55.6% | +28.1% | +19.3% | +56.4% | +31.3% | +80.6% | -55.6% | +22.2% | +34.7% | -20.0% | -32.9% | +62.1% | +67.6% | |
| – | +21.7% | -2.3% | -16.0% | -13.7% | -0.4% | +15.1% | +15.1% | -3.7% | -14.0% | -25.2% | +6.4% | -31.0% | +29.6% | -44.7% | -53.4% | +4.8% | -14.1% | +30.7% | +10.4% | +58.6% | +26.7% | +3.6% | +100.7% | -27.6% | -20.7% | +12.4% | -32.0% | -12.7% | +278.9% | |
| – | -1.0% | +64.4% | +64.5% | +25.0% | +0.9% | +21.1% | +46.4% | +57.1% | +11.8% | +131.7% | -87.8% | -21.8% | +28.0% | -2.4% | -49.6% | +7.6% | +11.6% | +25.5% | +8.0% | +9.2% | +7.6% | +31.7% | +11.0% | +43.3% | -22.0% | +49.7% | -24.7% | +49.0% | +17.5% | |
| – | +16.7% | +2.9% | -0.9% | -1.8% | -7.4% | +17.5% | +28.1% | +25.2% | +1.3% | +75.9% | -74.5% | -28.0% | +33.7% | -26.3% | -51.2% | +6.5% | +1.3% | +27.3% | +8.8% | +54.9% | +15.7% | +20.3% | -957.8% | – | -21.0% | +85.9% | -39.9% | +111.9% | +19.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +2,503.3% | +31.3% | +39.2% | +60.6% | +55.1% | +140.5% | +392.9% | -95.4% | +176.9% | -97.1% | +293.2% | -289.3% | – | |
| – | – | – | – | – | – | – | +74.3% | -100.0% | – | -4.7% | -93.1% | -72.5% | +33.7% | -78.5% | +4,224.1% | +31.8% | -37.2% | +134.0% | +142.8% | +3.2% | -6.4% | +323.5% | -26.0% | -23.3% | -28.4% | -90.8% | -63.5% | +363.0% | +55.3% | |
| – | – | – | – | – | – | – | – | – | – | -579.6% | – | – | – | – | – | – | – | +22.8% | +212.6% | -77.5% | +619.0% | +202.9% | +359.6% | -99.8% | +5,488.6% | -50.1% | +76.8% | -96.0% | +6,212.9% | |
| – | +1,477.3% | -30.4% | -61.9% | +44.0% | -25.0% | -57.5% | +116.5% | -98.7% | -74.7% | -65,208.5% | – | – | – | – | – | – | – | +9.6% | -53,660.0% | – | +332.6% | -32.8% | +457.6% | -103.2% | – | – | -76.1% | -33.4% | +426.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -134.8% | – | – | – | -105.2% | – | +5.3% | +2,039.9% | -100.6% | – | +1,041.5% | +339.1% | -100.5% | – | -158.4% | – | -107.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +126.6% | +423.1% | +13.3% | +28.2% | +84.2% | +47.1% | +193.6% | +267.7% | -93.5% | +151.9% | -43.1% | +24.2% | -59.5% | +372.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.